| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a89080b041791a137746ada0de593eb8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d6f7da1e425c8a3ef1da21e08f4c196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db9a3599f161df4befceab9c371abb0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44907280ee8f42b3cc36b0a7a2ebfaba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aeab358608f5a0a78f44d8d6c729f115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b3416da4f88b6bad53bd6e089faaf6f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 |
| filingDate |
2012-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72be37e66817b2bb85a1340a2efb9025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68fe60180e17a90cb8546024a80ee24d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eccabc42722f1b9098101ff4fbcf01ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b0b91a5b1a4c7f461bf5375d4606ef7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5faa1b5516da11fc0eb8cf326be56363 |
| publicationDate |
2012-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012116295-A1 |
| titleOfInvention |
Bone marrow-derived hematopoietic progenitor cells and endothelial progenitor cells as prognostic indicators for cancer |
| abstract |
Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1 + hematopoietic progenitor cells (HPCs) and/or VEGFR2 + endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer. |
| priorityDate |
2011-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |